Psychiatry 173 , 816826 (2016)
AQUA/WATER, CARNITINE, CITRIC ACID
The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321 A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies
It hits GLP-1 and GIP receptors with precision, and it has delivered some of the most impressive weight loss data the pharmaceutical world has seen
2.2 Data extraction and quality assessment The first authors last name, the publication year, the location of the study, the study design, the patient characteristics, the interventions, the diagnostic method, and the outcome measures, which included SD, mean, and 95% CI (the one that controlled for the most confounders), were all extracted from each study